Fludarabine, cyclophosphamide and rituximab (FCR) has been the standard of care for first‐line chronic lymphocytic leukemia (CLL) treatment for more than a decade and the latest European Society for Medical Oncology guidelines still consider FCR a therapeutic option for immunoglobulin heavy‐chain variable region gene (IGHV) mutated patients devoid of TP53 disruption. Exploiting a multicenter, real‐life cohort of CLL patients treated with FCR, we previously showed that IGHV mutated patients devoid of TP53 abnormalities and of 11q deletion can achieve a durable remission.8 In the present study, we updated the follow‐up of 301 CLL patients derived from the initial cohort.

Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia

Perbellini, Omar;Ferrarini, Isacco;Visco, Carlo;Rossi, Davide;
2022-01-01

Abstract

Fludarabine, cyclophosphamide and rituximab (FCR) has been the standard of care for first‐line chronic lymphocytic leukemia (CLL) treatment for more than a decade and the latest European Society for Medical Oncology guidelines still consider FCR a therapeutic option for immunoglobulin heavy‐chain variable region gene (IGHV) mutated patients devoid of TP53 disruption. Exploiting a multicenter, real‐life cohort of CLL patients treated with FCR, we previously showed that IGHV mutated patients devoid of TP53 abnormalities and of 11q deletion can achieve a durable remission.8 In the present study, we updated the follow‐up of 301 CLL patients derived from the initial cohort.
chronic lymphocytic leukemia, FCR, IGHV
File in questo prodotto:
File Dimensione Formato  
Hematological Oncology - 2022 - Moia - Long%E2%80%90term benefit of IGHV mutated patients in a real%E2%80%90life multicenter cohort of.pdf

solo utenti autorizzati

Tipologia: Documento in Pre-print
Licenza: Creative commons
Dimensione 552.39 kB
Formato Adobe PDF
552.39 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/1081767
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact